The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma

Neovascular Glaucoma Clinical Trial

Official title:

The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03154892
• Other study ID #: Conbercept Injection
• Status: Completed
• Phase: N/A
• Start date: April 1, 2017
• Est. completion date: December 31, 2017

Study information

• Verified date: May 2018
• Source: Second Affiliated Hospital of Xi'an Jiaotong University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.

Description:

The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，Its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. The intravitreal injection of anti-VEGF agent has shown its therapeutic potential for the early stage of NVG, but not for the late stage. Intracameral injection maybe used as an alternative way for administration. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 31, 2017
• Est. primary completion date: December 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with a diagnosis of neovascular glaucoma (Stage 1-2-3)

• Individuals who are ages 20-80 years old; male or female of chinese

• Visual acuity of light perception or better in the study eye

• Willing and able to comply with clinic visits and study-related procedures

• Provide signed informed consent

Exclusion Criteria:

• Use of intraocular anti-VEGF agents in the study eye in the past 3 months.

• Active ocular or periocular infection in the study eye

• Uncontrolled Blood Pressure

• Thromboembolism

• Congestive Heart Failure

• Renal Failure

• History of myocardial infarction

• History of Stroke

• Pregnant or breast-feeding women

• Participation in another simultaneous medical investigator or trial

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Neovascular
• Neovascular Glaucoma

Intervention

Procedure:
• Intracameral injection
Intracameral Conbercept injection for the treatment of NVG
• Intravitreal injection
Intravitreal Conbercept injection for the treatment of NVG

Locations

Country	Name	City	State
China	Department of Ophthalmology, Second affiliated hospital of Xian Jiaotong University	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
Second Affiliated Hospital of Xi'an Jiaotong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	NVI/NVA	Changes in extent of iris or angle neovascularization	1 week and 1 month after operation
Secondary	IOP	Changes in Intraocular pressure	1 week and 1 month after operation
Secondary	BCVA	Changes in best corrected visual acuity	1 week and 1 month after operation